达格列净与门冬胰岛素联合治疗2型糖尿病肥胖患者的疗效及安全性研究

Study on the Efficacy and Safety of Dapagliflozin Combined with Insulin Aspart in the Treatment of Obese Patients with Type 2 Diabetes Mellitus

目的研究达格列净联合门冬胰岛素在2型糖尿病肥胖患者治疗中的效果与安全性。方法选取2023年1月—2024年8月汉川市第二人民医院收治的96例糖尿病肥胖患者为研究对象,以不同的治疗方法分为两组,每组48例。常规组采用门冬胰岛素单独治疗,探究组采用达格列净与门冬胰岛素联合治疗。对比两组糖脂代谢水平及不良反应发生率。结果治疗后,探究组空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、甘油三酯及低密度脂蛋白胆固醇水平均低于常规组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论达格列净与门冬胰岛素联合治疗2型糖尿病肥胖患者,能够更有效地降低血糖和脂代谢水平,且安全性良好,为临床治疗提供了新的有效选择。

Objective To study the efficacy and safety of dapagliflozin combined with insulin aspart in the treatment of obese patients with type 2 diabetes mellitus.Methods A total of 96 obese patients with diabetes mellitus admitted to the Second People's Hospital of Hanchuan from January 2023 to August 2024 were selected as the research objects.They were divided into two groups according to different treatment methods,with 48 cases in each group.The routine group was treated with insulin aspart alone,and the exploration group was treated with dapagliflozin combined with insulin aspart.The levels of glucose and lipid metabolism and the incidence of adverse reactionswere compared between the two groups.Results After treatment,the levels of fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c,total cholesterol,triglyceride and low density lipoprotein cholesterol in the study group were lower than those in the routine group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with insulin aspart in the treatment of obese patients with type 2 diabetes mellitus can more effectively reduce blood glucose and lipid metabolism levels,and has good safety,which provides a new and effective choice for clinical treatment.